A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

by Ying Zhang, Ying Zhang, Ying Zhang, Jiaqi Li, Jiaqi Li, Jiaqi Li, Xiaoyan Lou, Xiaochen Chen, Xiaochen Chen, Xiaochen Chen, Zhou Yu, Liqing Kang, Jia Chen, Jia Chen, Jia Chen, Jin Zhou, Jin Zhou, Jin Zhou, Xiangping Zong, Xiangping Zong, Xiangping Zong, Zhen Yang, Zhen Yang, Zhen Yang, Minghao Li, Nan Xu, Sixun Jia, Sixun Jia, Sixun Jia, Hongzhi Geng, Hongzhi Geng, Hongzhi Geng, Guanghua Chen, Guanghua Chen, Guanghua Chen, Haiping Dai, Haiping Dai, Haiping Dai, Xiaowen Tang, Xiaowen Tang, Xiaowen Tang, Lei Yu, Lei Yu, Depei Wu, Depei Wu, Depei Wu, Caixia Li, Caixia Li, Caixia Li
Published 2021-05-01